OR WAIT null SECS
April 02, 2025
Article
This month in review spotlights phase 2 and 3 trials and discovered associations in the psychiatry field.
March 31, 2025
TSND-201 (methylone) met its primary endpoint in the phase 2 IMPACT-1 trial, showing rapid, significant PTSD symptom improvement with a good safety profile.
March 07, 2025
This month in review covers key psychiatry updates, including the latest FDA decisions, antidepressant use in pregnancy, and the latest episode of Medical Ethics Unpacked.
January 25, 2025
Women experience more severe early PTSD symptoms than men, with re-experiencing and avoidance clusters being strongest. Men showed stronger anxious arousal patterns.
December 29, 2024
This Year in Review features 2024 psychiatry highlights: FDA approvals, MDMA-assisted therapy setback, MM120 breakthrough, new CPT codes, and advances in schizophrenia treatments.
December 23, 2024
MDMA-assisted therapy, a source of hope for many, went on a tumultuous journey in 2024, going from historichype to setbacks.
December 19, 2024
A phase 3 trial shows promising data for brexpiprazole with sertraline for PTSD symptoms ahead of the supplemental new drug application’s PDUFA date in February 2024.
December 13, 2024
America's mental health crisis continues to escalate—what drives it, and what lies ahead in 2025? Hear insight from psychiatry and psychology experts.
December 09, 2024
A study found 66.4% of participants with probable PTSD had a life stressor of unwanted sexual experiences.
November 23, 2024
A recent study suggests ketamine can significantly improve symptoms of PTSD and OCD—but this is based on a review of an insufficient number of randomized controlled trials.
